SCHEMBL6336602

SCHEMBL6336602

C=CC/[C]=C/CC=CCC=CCCCCC

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.47
PPARG P37231 3/20 0.43
FFAR1 O14842 2/20 0.43
PPARD Q03181 2/20 0.43
PPARA Q07869 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
USP2 O75604 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
CYP3A4 P08684 1/20 0.43
MAPT P10636 1/20 0.43
HSPD1 P10809 1/20 0.43
CYP19A1 P11511 1/20 0.43
FABP4 P15090 1/20 0.43
HPGD P15428 1/20 0.43
ALOX15 P16050 1/20 0.43
CASP1 P29466 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1888612 0.85 TSHR (0.52) TRPV1PPARGALDH1A1PTGS1FAAH
SCHEMBL6347396 0.83 TSHR (0.56) TRPV1PPARGALDH1A1PTGS1FAAH
SCHEMBL7738560 0.83 TSHR (0.56) TRPV1PPARGALDH1A1PTGS1FAAH
SCHEMBL7853536 0.78 TSHR (0.68) TRPV1PPARGFFAR1PPARDPPARA
SCHEMBL14481041 0.78 TSHR (0.68) TRPV1PPARGFFAR1PPARDPPARA
SCHEMBL3341875 0.78
SCHEMBL19895424 0.78 TRPV1 (0.59) TRPV1PPARGFFAR1PPARDPPARA
SCHEMBL25185248 0.77 TSHR (0.65) TRPV1PPARGFFAR1PPARDPPARA
SCHEMBL19895405 0.77 TSHR (0.58) TRPV1PPARGFFAR1PPARDPPARA
SCHEMBL1296303 0.77 TSHR (0.73) TRPV1PPARGFFAR1PPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6911553-B1 Osteoblast-specific mitogens and drugs containing such compounds ROCHE DIAGNOSTICS GMBH (DE) 2005-06-28 US disclosed
US-20050014723-A1 Osteoblast-specific mitogens and drugs containing such compounds ESSWEIN ANGELIKA (DE) 2005-01-20 US disclosed
EP-1019062-B1 OSTEOBLAST-SPECIFIC MITOGENS AND DRUGS CONTAINING SUCH COMPOUNDS ROCHE DIAGNOSTICS GMBH (DE) 2003-02-05 EP disclosed
US-6444832-B1 OSTEOPOROSIS ESSWEIN ANGELIKA (DE) 2002-09-03 US disclosed
EP-0865422-B1 USE OF AMINOALCOHOLDERIVATIVES AS DRUGS, DERIVATIVES AND PROCESS FOR THEIR PREPARATION ROCHE DIAGNOSTICS GMBH (DE) 2001-07-11 EP disclosed
US-6197759-B1 ADMINISTERING LYSOPHOSPHATIDYLIC ACID DERIVATIVE ROCHE DIAGNOSTICS GMBH (DE) 2001-03-06 US disclosed
EP-0906759-A1 Novel osteoblastic specific mitogenes: process for their preparation and drugs containing these compounds Roche Diagnostics GmbH (DE) 1999-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014723-A1 Osteoblast-specific mitogens and drugs containing such compounds LPAR1, LPAR2, LPAR4 TRPV1 1233/4885PPARG 245/4885FFAR1 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.